Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Mitochondrial respiratory chain disease discrimination by retrospective cohort analysis of blood metabolites.
[pyruvate dehydrogenase deficiency]
Diagnosing
primary
mitochondrial
respiratory
chain
(
RC
)
dysfunction
has
long
relied
on
invasive
tissue
biopsies
,
since
no
blood
-based
biomarker
has
been
shown
to
have
sufficiently
high
sensitivity
and
specificity
across
the
myriad
of
individual
clinical
presentations
.
We
sought
to
determine
whether
cohort-level
evaluation
of
commonly
obtained
blood
analytes
might
reveal
consistent
patterns
to
discriminate
a
heterogenous
group
of
primary
mitochondrial
RC
disease
subjects
both
from
control
individuals
and
from
subjects
with
pyruvate
dehydrogenase
deficiency
.
F
ollowing
IRB
approval
,
62
biochemical
analyte
concentrations
or
ratios
were
retrospectively
analyzed
in
three
well-defined
and
intentionally
heterogeneous
subject
cohorts
reflective
of
clinical
practice
:
[
1
]
Primary
mitochondrial
disease
(
n
=
19
)
;
[
2
]
pyruvate
dehydrogenase
deficiency
(
n
=
4
)
;
and
[
3
]
controls
(
n
=
27
)
.
Blood
analyte
categories
included
comprehensive
chemistry
profile
,
creatine
kinase
,
lipoprotein
profile
,
lactate
,
pyruvate
,
and
plasma
amino
acid
profile
.
Non-parametric
analyses
were
used
to
compare
the
median
of
each
analyte
level
between
cohorts
.
Disease
cohorts
differed
significantly
in
their
median
levels
of
triglycerides
,
lactate
,
pyruvate
,
and
multiple
individual
plasma
amino
acids
.
Primary
mitochondrial
disease
was
significantly
discriminated
at
the
cohort
level
from
pyruvate
dehydrogenase
deficiency
by
greater
pyruvate
and
alanine
elevation
in
pyruvate
dehydrogenase
deficiency
,
as
well
as
significantly
increased
branched
chain
amino
acid
(
BCAA
)
levels
and
increased
ratios
of
individual
BCAAs
to
glutamate
in
mitochondrial
disease
.
In
addition
,
significant
elevation
of
median
blood
triglyceride
level
was
seen
in
the
primary
mitochondrial
disease
cohort
.
Blood
metabolite
profile
analysis
can
discriminate
a
heterogeneous
cohort
of
primary
mitochondrial
disease
both
from
controls
and
from
pyruvate
dehydrogenase
deficiency
.
Elevated
BCAA
levels
,
either
absolutely
or
when
considered
relative
to
the
level
of
glutamate
,
are
common
metabolic
sequelae
of
primary
mitochondrial
RC
disease
.
Prospective
study
is
needed
to
validate
observed
plasma
metabolite
alterations
as
a
potential
biomarker
of
disease
both
in
larger
cohorts
and
at
the
individual
subject
level
.
Diseases
Validation
Diseases presenting
"as well as significantly increased branched chain amino acid"
symptom
pyruvate dehydrogenase deficiency
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom